David S. Watt

Prof. David S. Watt


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2020 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
KHKaitlind C. Howard
Kaitlind C. Howard
EDEmily K. Dennis
Emily K. Dennis
DWDavid S. Watt
David S. Watt
SGSylvie Garneau-Tsodikova
Sylvie Garneau-Tsodikova
The emergence of new fungal pathogens makes the development of new antifungal drugs a medical imperative that in recent years motivates the talents of numerous investigators across the world.

9 July 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VSVitaliy M. Sviripa
Vitaliy M. Sviripa
WZWen Zhang
Wen Zhang
ABAndrii G. Balia
Andrii G. Balia
OTOleg V. Tsodikov
Oleg V. Tsodikov
JNJustin R. Nickell
Justin R. Nickell
DWDavid S. Watt
David S. Watt
Inhibition of the catalytic subunit of the heterodimeric methionine S-adenosyl transferase-2 (MAT2A) with fluorinated N,N-dialkylaminostilbenes (FIDAS agents) offers a potential avenue for the treatment of liver and colorectal cancers where upregulation of this enzyme occurs. A study of structure–activity relationships led to the identification of the most active compounds as those with (1) either a 2,6-difluorostyryl or 2-chloro-6-fluorostyryl subunit, (2) either an N-methylamino or N,N-dimethylamino group attached in a para orientation relative to the 2,6-dihalostyryl subunit, and (3) either an N-methylaniline or a 2-(N,N-dimethylamino)pyridine ring. These modifications led to FIDAS agents that were active in the low nanomolar range, that formed water-soluble hydrochloride salts, and that possessed the desired property of not inhibiting the human hERG potassium ion channel at concentrations at which the FIDAS agents inhibit MAT2A. The active FIDAS agents may inhibit cancer cells through alterations of methylation reactions essential for cancer cell survival and growth.

28 February 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
LGLichao Guo
Lichao Guo
WZWen Zhang
Wen Zhang
YXYanqi Xie
Yanqi Xie
XCXi Chen
Xi Chen
EOEmma E. Olmstead
Emma E. Olmstead
CLChunming Liu
Chunming Liu
Cancer cells undergo significant “metabolic remodeling” to provide sufficient ATP to maintain cell survival and to promote rapid growth. In colorectal cancer cells, ATP is produced by mitochondrial oxidative phosphorylation and by substantially elevated cytoplasmic glucose fermentation (i.e., the Warburg effect). Glucose transporter 1 (GLUT1) expression is significantly increased in colorectal cancer cells, and GLUT1 inhibitors block glucose uptake and hence glycolysis crucial for cancer cell growth. In addition to ATP, these metabolic pathways also provide macromolecule building blocks and signaling molecules required for tumor growth. In this study, we identify a diaminobutoxy-substituted isoflavonoid (DBI-1) that inhibits mitochondrial complex I and deprives rapidly growing cancer cells of energy needed for growth. DBI-1 and the GLUT1 inhibitor, BAY-876, synergistically inhibit colorectal cancer cell growth in vitro and in vivo. This study suggests that an electron transport chain inhibitor (i.e., DBI-1) and a glucose transport inhibitor, (i.e., BAY-876) are potentially effective combination for colorectal cancer treatment.

24 August 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
MFMykhaylo Frasinyuk
Mykhaylo Frasinyuk
WZWen Zhang
Wen Zhang
PWPrzemyslaw Wyrebek
Przemyslaw Wyrebek
TYTianxin Yu
Tianxin Yu
XXXuehe Xu
Xuehe Xu
CLChunming Liu
Chunming Liu
Cytisine-linked isoflavonoids (CLIFs) inhibit cancer cells by targeting the peroxisomal enzyme HSD17B4.

1 December 2020 in iScience
Verified
Journal Article
Open access
WZWen Zhang
Wen Zhang
VSVitaliy M. Sviripa
Vitaliy M. Sviripa
YXYanqi Xie
Yanqi Xie
TYTianxin Yu
Tianxin Yu
MHMeghan G. Haney
Meghan G. Haney
CLChunming Liu
Chunming Liu
Aberrant activation of Wnt signaling triggered by mutations in either Adenomatous Polyposis Coli (APC) or CTNNB1 (β-catenin) is a hallmark of colorectal cancers (CRC). As part of a program to develop epigenetic regulators for cancer therapy, we developed carboxamide-substituted benzhydryl amines (CBAs) bearing either aryl or heteroaryl groups that selectively targeted histone lysine demethylases (KDMs) and functioned as inhibitors of the Wnt pathway. A biotinylated variant of N-((5-chloro-8-hydroxyquinolin-7-yl) (4-(diethylamino)phenyl)-methyl)butyramide (CBA-1) identified KDM3A as a binding partner. KDM3A is a Jumonji (JmjC) domain-containing demethylase that is significantly upregulated in CRC. KDM3A regulates the demethylation of histone H3's lysine 9 (H3K9Me2), a repressive marker for transcription. Inhibiting KDM3 increased H3K9Me2 levels, repressed Wnt target genes, and curtailed in vitro CRC cell proliferation. CBA-1 also exhibited in vivo inhibition of Wnt signaling in a zebrafish model without displaying in vivo toxicity.

17 February 2016 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
MFMykhaylo Frasinyuk
Mykhaylo Frasinyuk
GMGalyna P. Mrug
Galyna P. Mrug
SBSvitlana P. Bondarenko
Svitlana P. Bondarenko
VKVolodymyr P. Khilya
Volodymyr P. Khilya
VSVitaliy M. Sviripa
Vitaliy M. Sviripa
DWDavid S. Watt
David S. Watt